HempMedsPX Will Exhibit Cannabidiol (CBD)-Rich Hemp Oil Products at Premier Spa and Wellness Event in Ft. Lauderdale, Fla.
SAN DIEGO, Sept. 20, 2013 (GLOBE NEWSWIRE) — Medical Marijuana Inc. (OTC Pink:MJNA) is pleased to announce to shareholders and the general public that HempMedsPX—a corporate portfolio company of Medical Marijuana Inc. and the exclusive master distributor and contracted marketing company for CannaVest Corp. (OTC:CANV) and Medical Marijuana Inc.—will be exhibiting Cibaderm, Cibdex and CanChew gum at the International Esthetics, Cosmetics & Spa Conference (IECSC) in Ft. Lauderdale, Florida from September 22-23, 2013.
“IECSC is the first exposure the spa industry will have to our unique CBD-rich hemp oil personal care and wellness supplements,” said Charles Vest, Director of Communications for HempMedsPX. “We are excited to have some of the top spa and wellness companies and buyers get to know us and the benefits of hemp-based CBD product lines for their businesses.”
Presented by American Spa, IECSC is expected to draw over 5,500 industry attendees from over two dozen countries, representing hundreds of spa and wellness companies. Now in its fifteenth year, IECSC is one of the most respected business and educational conferences for industry professionals to learn about the latest spa and wellness trends, techniques, and new spa products.
For more information about IECSC Florida, please visit their website: IECSC.com. For more information on the products being exhibited, please visit HempMedsPX.com or call 866-273-8502.
HempMedsPX offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMedsPX is a corporate portfolio company of Medical Marijuana Inc. (OTC:MJNA) and the exclusive master distributor and contracted marketing company for CannaVest Corp. (OTC:CANV) and Medical Marijuana Inc. In addition to handling sales and distribution of hemp cannabidiol (CBD) products, HempMedsPX is the communication hub for the Medical Marijuana Inc. family of companies.
About CanChew Biotechnologies
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products as well as food and nutraceutical products for general well-being.
The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewBiotech.com.
About Cannagum Marketing Group
Cannagum Marketing Group, a wholly-owned subsidiary of CanChew Biotechnologies, was incorporated to sell, market, and distribute CanChew gum. The company was formed to comply with federal regulations that require the company to clearly distinguish CanChew gum, a food product sold without claims, from MedChewRX, a pharmaceutical product that is in development by CanChew Biotechnologies. For more information, please visit CanChewBiotech.com.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
About CannaVest Corp.
CannaVest Corp. (OTC:CANV) is in the business of investing and developing hemp-based cannabinoid companies. CannaVest Corp. also develops, produces, markets and sells end-consumer products to the nutraceutical industry containing the hemp plant extract, cannabidiol (CBD). Additionally, the company resells—to third parties—raw product acquired by CannaVest Corp. pursuant to the company’s supply relationships in Europe. CannaVest Corp. seeks to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers. Cannabinoids (cannabidiol/CBD) are natural constituents of the hemp plant and CBD is derived from hemp stalk and seed. Additional information is available from OTCMarkets.com or by visiting CannaVest.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. and CannaVest Corp. to be materially different from the statements made herein.
Medical Marijuana, Inc., CannaVest Corp., and HempMedsPX do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell and distribute hemp-based products and are involved with Federally Legal Distribution of Medical Marijuana based products within certain international markets.
Investor relations contact:
Stuart T. Smith
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)